293 related articles for article (PubMed ID: 15862805)
1. Effect of celecoxib, a cyclooxygenase-2 inhibitor, on the pathophysiology of adjuvant arthritis in rat.
Noguchi M; Kimoto A; Kobayashi S; Yoshino T; Miyata K; Sasamata M
Eur J Pharmacol; 2005 Apr; 513(3):229-35. PubMed ID: 15862805
[TBL] [Abstract][Full Text] [Related]
2. Ulcerogenic influence of selective cyclooxygenase-2 inhibitors in the rat stomach with adjuvant-induced arthritis.
Kato S; Ogawa Y; Kanatsu K; Okayama M; Watanabe T; Arakawa T; Takeuchi K
J Pharmacol Exp Ther; 2002 Nov; 303(2):503-9. PubMed ID: 12388629
[TBL] [Abstract][Full Text] [Related]
3. The importance of brain PGE2 inhibition versus paw PGE2 inhibition as a mechanism for the separation of analgesic and antipyretic effects of lornoxicam in rats with paw inflammation.
Futaki N; Harada M; Sugimoto M; Hashimoto Y; Honma Y; Arai I; Nakaike S; Hoshi K
J Pharm Pharmacol; 2009 May; 61(5):607-14. PubMed ID: 19405999
[TBL] [Abstract][Full Text] [Related]
4. Micro-CT imaging analysis for the effect of celecoxib, a cyclooxygenase-2 inhibitor, on inflammatory bone destruction in adjuvant arthritis rats.
Noguchi M; Kimoto A; Sasamata M; Miyata K
J Bone Miner Metab; 2008; 26(5):461-8. PubMed ID: 18758904
[TBL] [Abstract][Full Text] [Related]
5. Nitric oxide (NO)-releasing naproxen (HCT-3012 [(S)-6-methoxy-alpha-methyl-2-naphthaleneacetic Acid 4-(nitrooxy)butyl ester]) interactions with aspirin in gastric mucosa of arthritic rats reveal a role for aspirin-triggered lipoxin, prostaglandins, and NO in gastric protection.
Fiorucci S; Di Lorenzo A; Renga B; Farneti S; Morelli A; Cirino G
J Pharmacol Exp Ther; 2004 Dec; 311(3):1264-71. PubMed ID: 15297470
[TBL] [Abstract][Full Text] [Related]
6. ABT-963 [2-(3,4-difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], a highly potent and selective disubstituted pyridazinone cyclooxgenase-2 inhibitor.
Harris RR; Black L; Surapaneni S; Kolasa T; Majest S; Namovic MT; Grayson G; Komater V; Wilcox D; King L; Marsh K; Jarvis MF; Nuss M; Nellans H; Pruesser L; Reinhart GA; Cox B; Jacobson P; Stewart A; Coghlan M; Carter G; Bell RL
J Pharmacol Exp Ther; 2004 Dec; 311(3):904-12. PubMed ID: 15277581
[TBL] [Abstract][Full Text] [Related]
7. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
Geis GS
J Rheumatol Suppl; 1999 Apr; 56():31-6. PubMed ID: 10225538
[TBL] [Abstract][Full Text] [Related]
8. Synergistic anti-hyperalgesia of electroacupuncture and low dose of celecoxib in monoarthritic rats: involvement of the cyclooxygenase activity in the spinal cord.
Mi WL; Mao-Ying QL; Liu Q; Wang XW; Wang YQ; Wu GC
Brain Res Bull; 2008 Sep; 77(2-3):98-104. PubMed ID: 18721668
[TBL] [Abstract][Full Text] [Related]
9. Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects.
Ushiyama S; Yamada T; Murakami Y; Kumakura S; Inoue S; Suzuki K; Nakao A; Kawara A; Kimura T
Eur J Pharmacol; 2008 Jan; 578(1):76-86. PubMed ID: 17920584
[TBL] [Abstract][Full Text] [Related]
10. Outcome of specific COX-2 inhibition in rheumatoid arthritis.
Lipsky PE; Isakson PC
J Rheumatol Suppl; 1997 Jul; 49():9-14. PubMed ID: 9249645
[TBL] [Abstract][Full Text] [Related]
11. The effects of some nonsteroidal anti-inflammatory drugs on experimental induced gastric ulcers in rats.
Batu OS; Erol K
Inflammopharmacology; 2007 Dec; 15(6):260-5. PubMed ID: 18236017
[TBL] [Abstract][Full Text] [Related]
12. Nonsteroidal anti-inflammatory drugs increase expression of inducible COX-2 isoform of cyclooxygenase in spinal cord of rats with adjuvant induced inflammation.
Hsueh SF; Lu CY; Chao CS; Tan PH; Huang YW; Hsieh SW; Hsiao HT; Chung NC; Lin SH; Huang PL; Lyu PC; Yang LC
Brain Res Mol Brain Res; 2004 Jun; 125(1-2):113-9. PubMed ID: 15193428
[TBL] [Abstract][Full Text] [Related]
13. [Prophylactic effect of a selective COX-2 inhibitor celecoxib on carcinogen-induced gastric premalignant lesions in rats].
Tang BD; Zeng ZR; Hu PJ
Ai Zheng; 2006 Oct; 25(10):1205-9. PubMed ID: 17059761
[TBL] [Abstract][Full Text] [Related]
14. In vivo selectivity of a selective cyclooxygenase 2 inhibitor in the oral surgery model.
Khan AA; Brahim JS; Rowan JS; Dionne RA
Clin Pharmacol Ther; 2002 Jul; 72(1):44-9. PubMed ID: 12152003
[TBL] [Abstract][Full Text] [Related]
15. Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention.
Kismet K; Akay MT; Abbasoglu O; Ercan A
Cancer Detect Prev; 2004; 28(2):127-42. PubMed ID: 15068837
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological profile of celecoxib, a specific cyclooxygenase-2 inhibitor.
Yoshino T; Kimoto A; Kobayashi S; Noguchi M; Fukunaga M; Hayashi A; Miyata K; Sasamata M
Arzneimittelforschung; 2005; 55(7):394-402. PubMed ID: 16080279
[TBL] [Abstract][Full Text] [Related]
17. Divergent roles of nitrergic and prostanoid pathways in chronic joint inflammation.
Day SM; Lockhart JC; Ferrell WR; McLean JS
Ann Rheum Dis; 2004 Dec; 63(12):1564-70. PubMed ID: 15547079
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibition of cyclooxygenase-2 with antisense oligodeoxynucleotide restricts induction of rat adjuvant-induced arthritis.
Yamada R; Sano H; Hla T; Hashiramoto A; Kawahito Y; Mukai S; Kohno M; Tsubouchi Y; Inoue M; Komatsu A; Inoue K; Kondo M
Biochem Biophys Res Commun; 2000 Mar; 269(2):415-21. PubMed ID: 10708568
[TBL] [Abstract][Full Text] [Related]
19. Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.
Gierse JK; Zhang Y; Hood WF; Walker MC; Trigg JS; Maziasz TJ; Koboldt CM; Muhammad JL; Zweifel BS; Masferrer JL; Isakson PC; Seibert K
J Pharmacol Exp Ther; 2005 Mar; 312(3):1206-12. PubMed ID: 15494548
[TBL] [Abstract][Full Text] [Related]
20. Treatment of painful temporomandibular joints with a cyclooxygenase-2 inhibitor: a randomized placebo-controlled comparison of celecoxib to naproxen.
Ta LE; Dionne RA
Pain; 2004 Sep; 111(1-2):13-21. PubMed ID: 15327804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
